Relief Therapeutics Holding AG (RLF.SW)
CHF 4.1
(-6.82%)
CHF 4.1
(-6.82%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | -10.85 Million CHF | 9.71% |
| 2022 | -12.02 Million CHF | -40.08% |
| 2021 | -8.58 Million CHF | 0.0% |
| 2020 | - CHF | 100.0% |
| 2019 | -1000.00 CHF | -100.2% |
| 2018 | 512 Thousand CHF | 17166.67% |
| 2017 | -3000.00 CHF | 98.47% |
| 2016 | -196 Thousand CHF | 89.27% |
| 2015 | -1.82 Million CHF | -126.83% |
| 2014 | 6.8 Million CHF | -7.01% |
| 2013 | 7.31 Million CHF | 484.49% |
| 2012 | -1.9 Million CHF | 0.0% |
| 2011 | - CHF | -100.0% |
| 2010 | 386.38 Thousand CHF | -97.19% |
| 2009 | 13.74 Million CHF | -5.53% |
| 2008 | 14.54 Million CHF | -1.9% |
| 2007 | 14.82 Million CHF | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | -903 Thousand CHF | 0.0% |
| 2023 Q2 | -5.71 Million CHF | 0.0% |
| 2023 FY | -10.85 Million CHF | 9.71% |
| 2023 Q4 | -5.14 Million CHF | 0.0% |
| 2022 FY | -12.02 Million CHF | -40.08% |
| 2022 Q2 | -5.22 Million CHF | 0.0% |
| 2022 Q4 | -6.8 Million CHF | 0.0% |
| 2021 Q2 | - CHF | 0.0% |
| 2021 Q4 | -3.11 Million CHF | 0.0% |
| 2021 FY | -8.58 Million CHF | 0.0% |
| 2020 Q2 | - CHF | 0.0% |
| 2020 FY | - CHF | 100.0% |
| 2020 Q4 | - CHF | 0.0% |
| 2019 Q2 | -1000.00 CHF | 0.0% |
| 2019 FY | -1000.00 CHF | -100.2% |
| 2019 Q4 | - CHF | 0.0% |
| 2018 Q2 | - CHF | 0.0% |
| 2018 Q4 | 512 Thousand CHF | 0.0% |
| 2018 FY | 512 Thousand CHF | 17166.67% |
| 2017 FY | -3000.00 CHF | 98.47% |
| 2017 Q4 | -71 Thousand CHF | 0.0% |
| 2017 Q2 | - CHF | 0.0% |
| 2016 Q1 | -49 Thousand CHF | 0.0% |
| 2016 FY | -196 Thousand CHF | 89.27% |
| 2016 Q2 | -49 Thousand CHF | 0.0% |
| 2016 Q4 | -196 Thousand CHF | 0.0% |
| 2015 Q3 | -476.3 Thousand CHF | -0.0% |
| 2015 FY | -1.82 Million CHF | -126.83% |
| 2015 Q1 | -476.3 Thousand CHF | -0.0% |
| 2015 Q4 | -49 Thousand CHF | 89.71% |
| 2015 Q2 | -476.3 Thousand CHF | 0.0% |
| 2014 Q4 | -476.3 Thousand CHF | -132.39% |
| 2014 FY | 6.8 Million CHF | -7.01% |
| 2014 Q3 | 1.47 Million CHF | -0.0% |
| 2014 Q2 | 1.47 Million CHF | 0.0% |
| 2014 Q1 | 1.47 Million CHF | -0.0% |
| 2013 Q4 | 1.47 Million CHF | -3.23% |
| 2013 Q3 | 1.51 Million CHF | -0.0% |
| 2013 Q2 | 1.51 Million CHF | 0.0% |
| 2013 Q1 | 1.51 Million CHF | -0.0% |
| 2013 FY | 7.31 Million CHF | 484.49% |
| 2012 FY | -1.9 Million CHF | 0.0% |
| 2012 Q4 | 1.51 Million CHF | 0.0% |
| 2012 Q2 | - CHF | 0.0% |
| 2012 Q1 | - CHF | 0.0% |
| 2012 Q3 | - CHF | 0.0% |
| 2011 Q2 | - CHF | 0.0% |
| 2011 Q4 | - CHF | 0.0% |
| 2011 FY | - CHF | -100.0% |
| 2011 Q3 | - CHF | 0.0% |
| 2011 Q1 | - CHF | 0.0% |
| 2010 Q1 | 96.59 Thousand CHF | 0.0% |
| 2010 Q4 | - CHF | -100.0% |
| 2010 Q3 | 96.59 Thousand CHF | 0.0% |
| 2010 Q2 | 96.59 Thousand CHF | 0.0% |
| 2010 FY | 386.38 Thousand CHF | -97.19% |
| 2009 Q2 | 3.43 Million CHF | 0.0% |
| 2009 Q3 | 3.43 Million CHF | 0.0% |
| 2009 Q4 | 96.59 Thousand CHF | -97.19% |
| 2009 FY | 13.74 Million CHF | -5.53% |
| 2009 Q1 | 3.43 Million CHF | 0.0% |
| 2008 Q4 | 3.43 Million CHF | -5.53% |
| 2008 Q2 | 3.63 Million CHF | 0.0% |
| 2008 Q1 | 3.63 Million CHF | 0.0% |
| 2008 FY | 14.54 Million CHF | -1.9% |
| 2008 Q3 | 3.63 Million CHF | 0.0% |
| 2007 FY | 14.82 Million CHF | 0.0% |
| 2007 Q3 | 3.7 Million CHF | 0.0% |
| 2007 Q2 | 3.7 Million CHF | 0.0% |
| 2007 Q1 | 3.7 Million CHF | 0.0% |
| 2007 Q4 | 3.63 Million CHF | -1.9% |
| 2006 Q4 | 3.7 Million CHF | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Addex Therapeutics Ltd | -5.31 Million CHF | -104.182% |
| BB Biotech AG | -199.56 Million CHF | 94.559% |
| Basilea Pharmaceutica AG | 130.84 Million CHF | 108.299% |
| Evolva Holding SA | -2.58 Million CHF | -320.468% |
| Idorsia Ltd | 145.23 Million CHF | 107.477% |
| Kuros Biosciences AG | 22.87 Million CHF | 147.477% |
| Molecular Partners AG | -40.8 Million CHF | 73.389% |
| Santhera Pharmaceuticals Holding AG | 99.54 Million CHF | 110.909% |